Reviewing CTI BioPharma Corp. (CTIC)’s and Its Rivals results

CTI BioPharma Corp. (NASDAQ:CTIC) is a company in the Biotechnology industry and that’s how we compare it to its competitors. The contrasting will be based on the dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Institutional & Insider Ownership

53.9% of CTI BioPharma Corp.’s shares are held by institutional investors. Comparatively, 53.20% of all Biotechnology’s companies shares are held by institutional investors. On other hand CTI BioPharma Corp. has 0.1% of its shares held by company insiders and an average of 8.45% insiders ownership for its competitors.


Table 1 has CTI BioPharma Corp. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CTI BioPharma Corp. 4,846,835,443.04% -61.30% -40.40%
Industry Average 812.10% 105.95% 28.39%

Earnings & Valuation

In next table we are contrasting CTI BioPharma Corp. and its competitors’ .

Net Income Gross Revenue Price/Earnings Ratio
CTI BioPharma Corp. 38.29M 1 0.00
Industry Average 33.76M 4.16M 35.97

Analyst Ratings

Table 3 shows breakdown of recent ratings for CTI BioPharma Corp. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CTI BioPharma Corp. 0 0 0 0.00
Industry Average 1.10 1.78 2.38 2.81

As a group, Biotechnology companies have a potential upside of 168.19%.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of CTI BioPharma Corp. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CTI BioPharma Corp. 0.72% -12.54% -24.64% -37.44% -67.32% -0.22%
Industry Average 5.82% 9.20% 28.08% 41.63% 73.35% 54.83%

For the past year CTI BioPharma Corp. has -0.22% weaker performance while CTI BioPharma Corp.’s competitors have 54.83% stronger performance.

Volatility & Risk

CTI BioPharma Corp. is 55.00% more volatile than S&P 500 because the stock has a beta of 1.55. In other hand, CTI BioPharma Corp.’s rivals have beta of 1.77 which is 76.75% more volatile than S&P 500.


CTI BioPharma Corp. does not pay a dividend.


CTI BioPharma Corp.’s peers show that they’re better in 4 of the 4 indicators compared to the company itself.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.